BMJ Open Association between diabetes mellitus and the risk for major cardiovascular outcomes and all-cause mortality in women compared with men: a metaanalysis of prospective cohort studies

Hao Wang, Ying Ba, Run-Ce Cai, Qian Xing

ABSTRACT

Objective Previous studies have reported sex differences in associations between diabetes mellitus (DM) and the risk of developing coronary heart disease (CHD) and stroke; however, the risk for cardiac death and all-cause mortality in women compared with men has not been reported. Therefore, this quantitative meta-analysis was performed to provide reliable estimates of sex differences in the effect of DM on major cardiovascular outcomes and all-cause mortality, irrespective of DM type. **Design** Meta-analysis.

Designi ivieta-arialysis.

Data sources The PubMed, Embase and the Cochrane Library databases were systematically searched in April 2018.

Eligibility criteria Investigations designed as prospective cohort studies that examined the association between DM and major cardiovascular outcomes and all-cause mortality stratified according to sex were included.

Data extraction and synthesis Data extraction and quality assessment were independently performed by 2 of the authors, and the relative risk ratio (RRR) obtained using a random effects model was used to measure sex differences in the associations of DM with major cardiovascular outcomes and all-cause mortality. Results Thirty prospective cohort studies that reported data from 1 148 188 individuals were included. The pooled women-to-men RRR suggested that female sex was associated with an increased risk for CHD (RRR 1.52(95% CI 1.32 to 1.76); p<0.001), stroke (RRR 1.23(95% CI 1.09 to 1.39); p=0.001), cardiac death (RRR 1.49(95% CI 1.11 to 2.00); p=0.009) and all-cause mortality (RRR 1.51(95% Cl 1.23 to 1.85); p<0.001). In addition, sex differences for the investigated outcomes in the comparison between DM and non-DM patients were variable after stratification of studies according to publication year, country, sample size, assessment of DM, follow-up duration, adjustment for important cardiovascular risk factors and study quality. **Conclusions** Findings of the present study suggested that women with DM had an extremely high risk for CHD, stroke, cardiac death and all-cause mortality compared with men with DM.

Strengths and limitations of this study

- Published studies with large sample sizes were included in the analysis, and findings of the present study were more robust than those of any individual study.
- All included studies were prospectively designed and population based, which mitigated, if not eliminated, the possibility of uncontrolled biases.
- Large studies with a diverse range of patient characteristics support the generalisability of the results because the populations included were distributed globally.
- Stratified results of sex differences between DM and major cardiovascular outcomes and all-cause mortality were calculated based on the study or patient characteristics.
- Heterogeneity of the included studies was resolved using multiple methods, and no publication bias was found, thus supporting the robustness of the pooled results.

INTRODUCTION

Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide and accounts for 10.3% of the global disease burden, with a mortality rate of approximately 30% at the first CVD event.^{1 2} Numerous studies have illustrated the risk for CVD and related factors in various populations.³⁻⁷ It has been established that the morbidity and mortality of CVD risk are significantly increased in patients with diabetes mellitus (DM).^{8–11} Furthermore, DM is an independent risk factor for CVD, all-cause mortality, blindness, kidney failure, amputation, fracture, frailty, depression, and cognitive decline,¹² thus emphasising the need to monitor high risk for CVD in patients with DM.

Sex differences in the effect of DM on the excess risk for coronary heart disease (CHD)

et al. Association between diabetes mellitus and the risk for major cardiovascular outcomes and all-cause mortality in women compared with men: a meta-analysis of prospective cohort studies. *BMJ Open* 2019;**9**:e024935. doi:10.1136/ bmjopen-2018-024935

To cite: Wang H, Ba Y, Cai R-C,

Prepublication history and additional material for this paper are available online. To view please visit the journal (http:// dx.doi.org/10.1136/bmjopen-2018-024935).

Received 21 June 2018 Revised 28 June 2019 Accepted 1 July 2019



© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

First Affiliated Hospital of Dalian Medical University, Dalian, China

Correspondence to Hao Wang; wanghaodl@126.com and stroke have been reported and vary based on several other risk factors.¹³ ¹⁴ These two large-scale quantitative meta-analyses reported that women with DM have a 44% and 27% greater risk for CHD and stroke, respectively. Although the mechanism of action remains unclear, the exposure effects may be influenced by non-DM women with persistently healthy lifestyles and are well controlled by other important cardiovascular risk factors.¹⁵ However, to our knowledge, several other important outcomes, including cardiac death and all-cause mortality, have not been examined in previous studies.

Although previous meta-analyses have illustrated sex differences in the association between DM and CHD and stroke risk, the current study is the first meta-analysis to quantify potential sex differences in cardiac death and all-cause mortality. Clarifying sex differences in DM and major cardiovascular outcomes and all-cause mortality is particularly important to identify high-risk populations for the development of major cardiovascular outcomes and all-cause mortality, given that it has not been definitively determined. Therefore, we performed a large-scale examination of available prospective cohort studies that examined sex-specific effects of DM on the subsequent risk for CHD, stroke, cardiac death and all-cause mortality to determine sex differences in DM regarding major cardiovascular outcomes and all-cause mortality.

MATERIAL AND METHODS

Data sources, search strategy and selection criteria

This study was conducted and is reported according to the meta-analysis of observational studies in epidemiology protocol.¹⁶ Studies with a prospective cohort design that analysed the associations between DM and CHD, stroke, cardiac death and all-cause mortality risk and were published in the English language were potentially eligible for inclusion in this meta-analysis. There were no restrictions on the publication status of the studies considered. Three electronic databases (PubMed, Embase and the Cochrane Library) were searched for studies published from inception to April 2018 using the following search terms: ('diabetes mellitus' OR 'diabetes') AND ('Coronary Disease' OR 'Coronary Artery Disease' OR 'Myocardial Ischemia' OR 'stroke' OR 'death' OR 'mortality') AND ('men' OR 'male') AND ('women' OR 'female') AND ('Cohort Studies' OR 'Prospective Studies') AND 'human' AND 'English'. The details of the strategy used to search PubMed are presented in online supplementary file 1. Additional eligible studies were identified by manual searches of the reference lists in the relevant original and review articles. The study title, design, exposure, control and outcomes of varying effects in men and women in these studies were separately considered in selecting relevant studies.

The literature search and study selection were performed independently by two reviewers; any disagreement between these reviewers was resolved by including the corresponding author in the discussion until consensus was reached. The inclusion criteria were as follows: design: prospective cohort design; exposure and control: DM (irrespective of DM type) and non-DM; outcomes: CHD, stroke, cardiac death and all-cause mortality; and effect estimate: the relationship between DM and CHD, stroke, cardiac death, and all-cause mortality in men and women were reported separately. Studies examining single-sex populations, those with retrospective observational designs and reported with standard incidence/ mortality ratio were excluded.

Data collection and quality assessment

Two independent reviewers performed data collection and quality assessment, and any inconsistencies was adjudicated by referring to the original studies. The collected data included the first author or study group's name, publication year, country, sample size, age range, percentage of women, number of DM subjects, assessment of DM, follow-up duration, adjusted factors and investigated outcomes. The effect estimate was selected and maximally adjusted for confounders if the study reported several multivariable adjusted effect estimates. Quality assessment was performed using the Newcastle-Ottawa Scale, which is based on selection (four items), comparability (one item) and outcome (three items).¹⁷ A 'star system' (range: 0–9) was used to evaluate individual study quality.

Statistical analysis

Sex differences in the relationship between DM and CHD, stroke, cardiac death or all-cause mortality risk were based on the sex-specific effect estimate and corresponding 95% CI of each individual study. Given the low prevalence of CHD, stroke, cardiac death or all-cause mortality, ORs could be assumed to be accurate estimates of RR. Furthermore, HR was regarded to be equivalent to Relative Risk (RR) in studies with a cohort design. The summary RRs and 95% CIs for DM versus non-DM and the risk for CHD, stroke, cardiac death and all-cause mortality in men and women were calculated separately using a random-effects model, and the STATA commands were metan lnrr lnrrl lnrru, eform random xlab (0.3, 0.5, 1.0, 2.0) effect (RR) label (namevar=study).^{18 19} The femaleto-male ratio of RRs (ie, relative risk ratio (RRR)) and 95% CI in each study for CHD, stroke, cardiac death or all-cause mortality were then calculated based on sex-specific RRs and 95% CIs.^{14 15 20} Finally, the summary RRR and 95% CIs for sex differences in DM versus non-DM and CHD, stroke, cardiac death or all-cause mortality risk were calculated using a random-effects model.^{18 19}

The I² and Q statistics were used to evaluate heterogeneity among the included studies; those with p<0.10 were considered to demonstrate significant heterogeneity.^{21 22} A sensitivity analysis was then conducted to evaluate the impact of individual studies on the overall estimates by excluding each study sequentially.²³ Subsequently, subgroup analyses for sex differences in DM on CHD, stroke, cardiac death or all-cause mortality risk were calculated based on the following: publication year (2010 or after, and before 2010); country (Eastern or Western countries); sample size (\geq 10000 and <10000); assessment of DM (self-reported, measured or both); follow-up duration (\geq 10 and <10 years); adjustment for other cardiovascular risk factors (yes or no); and study quality (high vs low). Finally, publication biases for investigated outcomes were assessed using funnel plots, the Egger test and the Begg test.^{24 25} Two-sided p values with a significance level of 0.05 were used in the pooled analyses. Statistical analyses were performed using STATA software V.10.0.

Patient and public involvement

No patients were involved in the development of the research question, outcome measures, design, study implementation, dissemination of the results of the research to the study participants or interpretation of the results.

RESULTS

Literature search

The study selection process is shown in online supplementary file 2. A total of 13 471 articles were identified in the initial electronic search, of which 12745 were excluded due to duplicates and irrelevant topics. The abstracts of the remaining 726 articles were assessed, and 633 were excluded due to having a design other than prospective cohort and reported cardiovascular risk factors as outcomes. The full text was retrieved for the remaining 93 articles to identify potential studies that may be included. Thirty prospective cohort studies fulfilled the inclusion criteria and were ultimately included in the meta-analysis.^{26–55} There was no additional eligible studies after a manual search of the reference lists of these studies.

Study characteristics

A total of 30 studies, which included 75 cohorts, 1 148 188 individuals and 52 715 DM patients were included. Table 1 summarises the baseline characteristics of the included studies. The follow-up period was 5.0–30.0 years, while 787–436 832 individuals were included in each study. Forty-one cohorts were from countries in the Western countries, and the remaining 34 from the Eastern countries. The percentage of women ranged from 33.0% to 63.0%. Nine studies used self-reported methods to assess DM, 16 studies used medical methods and the remaining 5 used both self-reported and medical methods. Overall, 9 studies had a Newcastle-Ottawa Scale score of 8, 12 studies had a score of 6 (online supplementary file 3).

Coronary heart disease

Twenty studies reported sex differences in the association between DM and subsequent CHD risk. Summaries of the results in men and women are shown separately in online supplementary file 4. The results indicated that DM was associated with an increased risk for CHD risk in both men and women. Furthermore, the pooled RRR (female to male) of DM versus non-DM and the risk for CHD was 1.52 (95% CI 1.32 to 1.76; p<0.001) (figure 1A). Although the difference was statistically significant, there was significant heterogeneity among the studies (I^2 =36.1%; p=0.044). Results of the sensitivity analysis were not affected after sequential exclusion of each study from the pooled analyses (online supplementary file 5). The results of subgroup analyses were consistent with the overall analysis in most subsets, except for follow-up duration <10.0 years (table 2).

Stroke

Twenty studies reported sex differences in the association between DM and subsequent risk for stroke. The pooled results in men and women with DM were statistically significant (online supplementary file 4). The pooled RRR (female to male) suggested that women with DM had an increased risk for stroke compared with men with DM (RRR 1.23 (95% CI 1.09 to 1.39); p=0.001) (figure 1B), and no evidence of heterogeneity was observed ($I^2=0.0\%$; p=0.568). Sensitivity analysis indicated that the conclusion was not affected by sequential exclusion of each study from the pooled analyses (online supplementary file 5). Subgroup analysis indicated no sex differences in the relationship between DM and stroke risk for pooled studies published in 2010 or after, conducted in the Eastern hemisphere, sample sizes <10000, those that used both self-reported and measured parameters, duration of follow-up <10.0 years, no adjustments for other cardiovascular risk factors and those of low quality (table 3).

Cardiac death

Ten cohort studies reported sex differences in the association between DM and subsequent risk for cardiac death. DM was associated with a greater risk for cardiac death in men and women independently (online supplementary file 4). The pooled RRR (female to male) of DM versus non-DM for risk for cardiac death was 1.49~(95%)CI 1.11 to 2.00; p=0.009) (figure 2A), which was a statistically significant difference; furthermore, non-significant heterogeneity was detected ($I^2=31.9\%$; p=0.153). Results of the sensitivity analysis were altered after excluding the Kuopio and North Karelia studies (online supplementary file 5). Subgroup analysis indicated significant sex differences in DM in cardiac death if the study was published before 2010, was conducted in the Western hemisphere, had a sample size ≥ 10000 , used medical measures to assess DM, had a follow-up duration ≥ 10.0 years, was adjusted for other cardiovascular risk factors and was of high quality (table 4).

All-cause mortality

Seven cohort studies reported sex differences in the association between DM and subsequent all-cause mortality risk. Results indicated that DM was associated with a higher risk for all-cause mortality in men and women independently (online supplementary file 4). The pooled

Ex P ⁿ 198 USA 7381 407 40-77 55.0 Self-reported 9.0 o Bernado ⁷ 198 USA 3778 320 50-79 5.0 Self-reported 10.0 ist Heatth Study ⁶ 1989 USA 5131 1266 55.0 Measured 10.0 s ^m 1992 USA 5131 1266 58.0 Measured 10.0 s ^m 1992 USA 513 1266 58.0 Measured 10.0 s ^m 1992 USA 781 286 58.0 Measured 6.0 s ^m 1993 USA 781 38 58.0 Measured 50.0 study ⁴ 1993 USA 787 38 58.0 Measured 50.0 study ⁴ 1994 USA 787 38 58.0 Measured 50.0 study ⁴ 1994 USA 787 37 58.0 Measured 50.0	Percentage Publication Sample Number Age of women Study vear Country size of DM range (%)	Publication vear	Country	Sample size	Number of DM	Age range	Percentage of women (%)	Assessment of DM	Follow-up duration (vears)	Adjusted factors	Study quality
Bernado ²⁷ 198 USA 3778 320 6-79 6-10 Seft-reported 12.0 1989 USA 15726 1610 55.0 Measured 18.0 1989 USA 5131 1266 >25 55.0 Measured 10.0 10 USA 5131 1266 >55 58.0 Measured 10.0 10 USA 5131 1266 55.0 Measured 10.0 10 USA 1394 2316 58.0 Measured 10.0 10 USA 1394 318 36.0 Measured 30.0 10 USA 1394 318 316 31.0 Measured 30.0 10 USA 1394 318 31.0 Measured 30.0 10 USA 1394 31.0 Measured 30.0 10.0 11 USA 1394 139 31.0 Measured 31.0 1	NHANES 1 ²⁶	1988	USA	7381	407	40-77	55.0	Self-reported	9.0	Age, SBP, smoking, BMI and TC.	7
1980 USA 15 72 16 10 5-64 5.0 Measured 18.0 at Health Study ² 1992 USA 27 658 656 >25 63.0 Measured 6.0 model 1992 USA 5131 1266 5-84 52.0 Measured 6.0 model 1992 USA 2812 386 >56.0 Measured 6.0 model 1993 USA 1394 281 38.0 Measured 30.0 ton Heart Study 1993 USA 1804 18.0 18-90 30.0 ton Heart Study 1993 USA 18.0 18-90 40.0 30.0 study ⁴ 1993 USA 18-00 18-00 Measured 30.0 study ⁴ 1995 Australia 2805 26.0 Measured 11.0 Molanesized 1996 Fiji 1220 18-0 Measured 11.0 Molanesized 1996 Fij	Rancho Bernado ²⁷	1988	NSA	3778	320	50-79	54.0	Self-reported	12.0	Age, SBP, TC, smoking, obesity, family history and oestrogen use.	Q
Heatth Study ^a 1992 USA 27658 656 >25 6.10 Measured 6.0 1992 USA 5131 1266 15-84 52.0 Measured 10.0 1992 USA 2812 386 55.0 Measured 10.0 1992 USA 787 38 >35 58.0 Measured 30.0 114attStudy 1993 USA 787 37 58.0 Measured 30.0 114attStudy 1993 USA 787 37 58.0 Measured 10.0 1143 1994 USA 787 37 58.0 Measured 10.0 1144 1995 USA 787 2805 206 Measured 10.0 1144 1995 Australia 2805 206 Measured 10.0 1145 1996 Fiji 1220 126 126 Measured 10.0 11464 130 2805	ARIC ²⁸	1989	NSA	15732	1610	45-64	55.0	Measured	18.0	Age, SBP, smoking, BMI and TC.	7
1992 USA 5131 1266 15-84 5.0 Measured 10.0 1993 USA 2812 386 >55 58.0 Self-reported 6.0 1993 USA 2812 386 >55 58.0 Self-reported 6.0 1 1993 USA 1384 38 >35 58.0 Measured 30.0 11** 1993 USA 18603 1290 18-90 46.0 Self-reported 30.0 11** 1995 Australia 2805 206 >60 Measured 13.0 11** 1995 Australia 2805 206 56.0 Measured 10.0 11*** 1996 Fiji 1220 16 20.0 50.0 Measured 10.0 15 1996 Fiji 1324 55.0 Measured 10.0 10.0 16 130 1200 18-90 46.0 56.0 Measured 10.	Adventist Health Study ²⁹	1992	NSA	27 658	656	>25	63.0	Measured	6.0	Age, hypertension, smoking, BMI and PA.	d 6
1993 USA 2812 386 >55 58.0 Seff-reported 6.0 In Heart Study- 1993 USA 1394 38 >35 53.0 Measured 30.0 In Heart Study- 1993 USA 787 37 37 35 58.0 Measured 30.0 Il ¹³ 1994 USA 787 37 37 36.0 Measured 30.0 130 udy ³⁴ 1995 Vustralia 2805 206 56.0 Measured 13.0 130 udy ³⁴ 1996 Fiji 1220 166 >50 Measured 10.0 11.0 dians ³⁵ 1996 Fiji 1220 166 >50.0 55.0 Measured 10.0 elanesians ³⁵ 1996 Fiji 1220 166 >50.0 55.0 Measured 50.0 50 study ³⁴ 2002 Japan 3905 174 25.74 51.0 Self-reported 16.0 study ³⁴ 2002 Japan 32.76 Self-reported	Sievers ³⁰	1992	NSA	5131	1266	15-84	52.0	Measured	10.0	Age	7
In Heart Study- 1993 USA 1394 38 >35 53.0 Measured 30.0 In Heart Study- 1993 USA 787 37 >35 58.0 Measured 30.0 Ill ³ 1994 USA 787 37 >35 58.0 Measured 30.0 Ill ³ 1994 USA 18603 1290 18-90 46.0 Self-reported 13.0 udy ³⁴ 1995 Australia 2805 206 >60 50.0 Measured 5.0 dians ³⁵ 1996 Fiji 1220 166 >20.0 55.0 Measured 10.0 10 dians ³⁵ 1996 Fiji 1220 166 >50.0 Measured 11.0 10 dians ³⁵ 1996 Fiji 1220 166 >50.0 Measured 11.0 10 study ³⁴ 1996 Fiji 1324 65 >20.0 56.0 Measured 11.0 study ³⁴ 2002 Japan 92.7 50.0 56.0 Measu	EPESE ³¹	1993	NSA	2812	386	>65	58.0	Self-reported	6.0	Age, AHT use, smoking, BMI, diabetes, angina and chest pain on exertion.	Q
In Heart Study- 1993 USA 787 37 >35 58.0 Measured 30.0 Ill ³ 1994 USA 18603 1290 18-90 46.0 Self-reported 13.0 $armasured$ 30.0 udy ³⁺¹ 1995 Australia 2805 206 56.0 Measured 1.0 $armasured$ 1.0	Charleston Heart Study- White ³²	1993	NSA	1394	38	>35	53.0	Measured	30.0	Age.	9
III ³ 1994 USA 18603 1290 18-90 46.0 5eff-reported 13.0 udy^{34} 1995 Australia 2805 206 >60 56.0 Measured 5.0 $dians^{35}$ 1996 Fiji 1220 166 >20.0 55.0 Measured 1.0 $dians^{35}$ 1996 Fiji 1220 166 >5.0 Measured 1.1 1.0 $dians^{35}$ 1996 Fiji 1220 166 >6.0 56.0 Measured 1.0 1.0 $elanesians^{35}$ 1996 Fiji 1324 65 >20.0 53.0 Measured 10.0 10 $study^{34}$ 2002 Japan 927 169 40-79 56.0 Measured 10.0 10 $study^{34}$ 2002 Japan 927 169 40-79 56.0 or measured 17.0 10 $study^{34}$ 2002 Japan 235 25.0 52.0 or measured 17.0 10 $study^{34}$ 2002	Charleston Heart Study- Black ³²	1993	NSA	787	37	>35	58.0	Measured	30.0	Age.	9
udy ³⁴ 1995 Australia 2805 206 50 Measured 5.0 dians ³⁵ 1996 Fiji 1220 166 > 20.0 55.0 Measured 11.0 elanesians ³⁵ 1996 Fiji 1220 166 > 20.0 5.0 Measured 11.0 elanesians ³⁵ 1996 Fiji 1324 65 > 20.0 5.0 Measured 11.0 11.0 study ³⁴ 1998 Sweden 39055 174 $25-74$ 51.0 Self-reported $10-18$ os Angeles- 2002 Japan 927 169 $40-79$ 56.0 Measured 10.10 study ³⁴ 2002 leand 18519 295 $32-60$ 52.0 56.0 50.0 50.0 50.0 study ³⁴ 2002 leand 18519 295 $22-60$ 52.0 50.0 50.0 50.0 50.0 50.0 50.0 50.0 50.0 50.0 50.0 50.0 50.0 50.0	NHANES III ³³	1994	NSA	18 603	1290	18-90	46.0	Self-reported or measured	13.0	Age, SBP, smoking, BMI and TC.	7
dians ⁵⁵ 1996 Fij 1220 166 >20.0 55.0 Measured 11.0 elanesians ³⁵ 1996 Fiji 1324 65 >20.0 53.0 Measured 11.0 elanesians ³⁵ 1998 Sweden 39055 174 $25-74$ 51.0 Self-reported 16.0 study ³⁷ 2002 Japan 927 169 $40-79$ 56.0 Measured 10-18 study ³⁸ 2002 Isaban 927 169 $40-79$ 56.0 Measured 10-18 study ³⁸ 2002 Isaban 927 169 $20-79$ 56.0 Measured 10-18 study ³⁸ 2002 Isaban 927 169 $20-79$ 56.0 Measured 10-18 study ³⁸ 2002 Isaban 927 9260 52.0 Self-reported 17.0 study ³⁸ 2003 27 817 70 Self-reported 17.0 study ³⁸ 203 27 32.0 53.0 53.0 Self-reported 17.0	Dubbo study ³⁴	1995	Australia	2805	206	>60	56.0	Measured	5.0	Age, AHT use, BMI, TC, HDL, triacylglycerols, ApoB, LPa, diabetes, self-rated health and prior CH.	0
letanesians ³⁵ 1996 Fiji 1324 65 >20.0 53.0 Measured 11.0 1998 Sweden 39055 174 $25-74$ 51.0 Self-reported 16.0 1998 Sweden 39055 174 $25-74$ 51.0 Self-reported 16.0 10 Aban 927 169 $40-79$ 56.0 Measured $10-18$ 10 study ³ 2002 leand 18519 295 $32-60$ 52.0 0 measured 17.0 study ³ 2002 leand 18519 295 $32-60$ 52.0 0 measured 17.0 study ³ 2003 27 436832 17763 32.0 33.0 0 0 0 0 study ³ 2003 27 436832 17763 >20 33.0 0 0 0 0 study ³ 0 0 0 0 0 0 0 0 0 0 0 0 0 </td <td>Collins-Indians³⁵</td> <td>1996</td> <td>Fiji</td> <td>1220</td> <td>166</td> <td>>20.0</td> <td></td> <td>Measured</td> <td>11.0</td> <td>Age, SBP, smoking, BMI, TC and survey area.</td> <td>Q</td>	Collins-Indians ³⁵	1996	Fiji	1220	166	>20.0		Measured	11.0	Age, SBP, smoking, BMI, TC and survey area.	Q
1998Sweden39055174 $25-74$ 51.0 Self-reported 16.0 56.0 Japan927169 $40-79$ 56.0 Measured $10-18$ $study^{36}$ 2002Japan18519295 $32-60$ 52.0 Self-reported 17.0 $study^{36}$ 2002Iceland18519295 $32-60$ 52.0 Self-reported 17.0 $study^{36}$ 2003 27 436832 17763 >20 52.0 Self-reported 7.0 sia^{39} 203 27 436832 17763 >20 33.0 Self-reported 7.0 sia^{39} 203 27 436832 17763 >20 33.0 Self-reported 7.0	Collins-Melanesians ³⁵	1996	Fiji	1324	65	>20.0	53.0	Measured	11.0	Age, SBP, smoking, BMI, TC and survey area.	9
geles- by ³ 2002 Japan 927 169 40–79 56.0 Measured 10–18 y ³ 2002 lceland 18519 295 32–60 52.0 Self-reported 17.0 2003 27 436832 17763 >20 33.0 Self-reported 7.0 2003 27 436832 17763 >20 33.0 Self-reported 7.0	SALLS ³⁶	1998	Sweden	39 055	174	25-74	51.0	Self-reported	16.0	Age.	9
y ³⁸ 2002 Iceland 18519 295 32–60 52.0 Self-reported 17.0 or measured 27.0 2003 27 436832 17763 >20 33.0 Self-reported 7.0 cohorts in Asia	Hawaii-Los Angeles- Hiroshima study ³⁷	2002	Japan	927	169	40-79	56.0		10–18	Age, hypertension, smoking, BMI, TC, triacylglycerols, uric acid and ECG abnormalities.	9
2003 27 436 832 17 763 >20 33.0 Self-reported 7.0 cohorts or measured in Asia	Reykjavik study ³⁸	2002	Iceland	18519	295	32-60	52.0	Self-reported or measured	17.0	Age, hypertension, smoking, BMI, TC, triacylglycerols, diabetes, glucose, prior CHD and LVH.	ω
	APCSC-Asia ³⁹	2003	27 cohorts in Asia	436 832	17 763	>20	33.0	Self-reported or measured	7.0	Age, SBP, smoking, BMI and TC.	7

Study	Publication year	Country	Sample size	Number of DM	Age range	Percentage of women (%)	Assessment of DM	Follow-up duration (years)	Adjusted factors	Study quality
APCSC-Australia and New Zealand ³⁹	2003	Nine cohorts in Australia and New Zealand	99 624	4784	>20	45.0	Self-reported or measured	7.0	Age, SBP, smoking, BMI and TC.	2
Framingham study ⁴⁰	2003	Two cohorts in USA	5243	229	35-75	52.0	Measured	20.0	Age, hypertension, smoking, BMI and TC.	2
lso ⁴¹	2004	Japan	10582	267	4069	60.0	Measured	17.0	Age, hypertension, smoking, BMI, TC, HDL, skinfold, alcohol, community and menopause.	ω
Renfrew and Paisley Survey ⁴²	2005	Scotland	15426	228	4564	54.0	Self-reported or measured	25.0	Age, SBP, smoking, BMI, TC and SES.	8
Kuopio and North Karelia ⁴³	2005	Finland	51 735	1108	25–74	51.0	Self-reported	17.0	Age, SBP, smoking, BMI, TC and study year.	ω
Strong Heart Study ⁴⁴	2006	NSA	4372	724	45–74	61.0	Measured	12.0	Age, SBP, DBP, smoking, HDL, LDL and albuminuria.	7
Framingham Offspring ⁴⁵	2006	NSA	2097	66	50-81	50.0	Measured	14.0	Age, SBP, AHT, CVD, atrial fibrillation, LVH and smoking.	7
San Antonio Heart Study ⁴⁶	2007	NSA	4996	524	25–64	57.0	Measured	16.0	Age and ethnicity.	7
SHHEC ⁴⁷	2007	Scotland	13 343	184	30–74	51.0	Measured	16.0	Age, SBP, smoking, BMI and TC.	7
EPIC-Norfolk ⁴⁸	2008	Х	22 516	441	40–79	55.0	Self-reported	10.0	Age, SBP, smoking, BMI, TC and triglycerides.	ω
Takayama ⁴⁹	2008	Japan	29 079	1217	>35	54.0	Self-reported	7.0	Age, hypertension, smoking, BMI, PA, education, energy, vegetables, fat and alcohol.	ω
DECODE ⁵⁰	2009	Seven cohorts in Finland and Sweden	9278	826	4069	55.0	Measured	5-21	Age, hypertension, smoking, BMI, TC and HDL.	Q
Hisayama ⁵¹	2010	Japan	2421	291	40-79	57.0	Measured	14.0	Age, SBP, smoking, BMI, TC, HDL, alcohol intake, PA and ECG abnormalities.	7
									0	Continued

6

Open access

Table 1 Continued										
Study	Publication year	Country	Sample size	Number Age of DM rang	Age range	Percentage of women (%)	Follow-u Assessment duration of DM (years)	Follow-up duration (years)	Adjusted factors	Study quality
JPHC ⁵²	2011	Two cohorts in Japan	35 657	2034	40-69	63.0	Measured	12.0	Age, SBP, AHT, smoking, BMI, TC, HDL, triglycerides, alcohol, fasting status and residential areas.	ω
HUNT 1 ⁵³	2012	Norway	47 951	1992	>20	52.0	Self-reported	17.0	Age, hypertension, smoking, BMI, CVD and PA.	ω
ESPro ⁵⁴	2017	Germany 105 000	105 000	7190	>18	51.0	Self-reported or measured	14.0	Calendar year and age.	7
JACC ⁵⁵	2017	Japan	104 910	5729	40-79	58.0	Self-reported	19.0	Age, education, smoking, alcohol, PA, BMI, history of hypertension or history of DM.	ω
AHT, antihypertensive; APCSC, Asia Pacific Cohort Studies Collaboration; ApoB, apolipoprotein B; ARIC, Atherosclerosis Ris disease; DBP, diastolic blood pressure; DECODE, Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Euro Epidemiology Studies of the Elderly; EPIC, European Prospective Investigation into Cancer; HDL, high-density lipoprotein; J/L LP, lipoprotein a; LVH, left ventricle hypertrophy; NA, not available; NHANES, National Health and Nutrition Examination Sur Survey; SBP, systolic BP; SES, socioeconomic status; SHHEC, Scottish Heart Health Extended Cohort; TC, total cholesterol.	SC, Asia Pacific (od pressure; DEC(e Elderly; EPIC, Er ventricle hypertro ES, socioeconom	Cohort Studi ODE, Diabett uropean Pro: ophy; NA, no iic status; SH	es Collabore es Epidemio spective Inve t available; N	ation; ApoB, logy: Collab estigation in vHANES, Ni ish Heart He	apolipopr norative an ito Cancer ational He: atth Exten	otein B; ARIC, / alysis of Diagno ; HDL, high-den alth and Nutritio ded Cohort; TC	Atherosclerosis Ristic criteria in Eur sitic criteria in Eur sity lipoprotein; J, n Examination Su total cholesterol	sk in Commun ope; DM, diab ACC, Japan C rvey; PA, phys	AHT, antihypertensive; APCSC, Asia Pacific Cohort Studies Collaboration; ApoB, apolipoprotein B; ARIC, Atherosclerosis Risk in Communities; BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; DECODE, Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe; DM, diabetes mellitus; EPESE, Established Populations for Epidemiology Studies of the Elderly; EPIC, European Prospective Investigation into Cancer; HDL, high-density lipoprotein; JACC, Japan Collaborative Cohort; LDL, low-density lipoprotein; LPa, lipoprotein at LVH, left ventricle hypertrophy; NA, not available; NHANES, National Health and Nutrition Examination Survey; PA, physical activity; SALLS, Swedish Annual Level-of-Living Survey; SBP, systolic BP; SES, socioeconomic status; SHHEC, Scottish Heart Health Extended Cohort; TC, total cholesterol.	scular ns for otein; of-Living

<u>6</u>

for risk for all-cause mortality between participants with DM and those without DM (RRR 1.51 (95% CI 1.23 to 1.85); p<0.001) (figure 2B), with moderate heterogeneity among the included studies (I^2 =38.2%; p=0.138). Sensitivity analysis revealed that the conclusion was not affected by the exclusion of any specific study (online supplementary file 5). Subgroup analyses indicated no sex difference if the study was conducted in the Eastern hemisphere, with a sample size <10000, used medical measure to assess DM, was not adjusted for other cardiovascular risk factors and was of low quality (table 5).

female-to-male RRR indicated significant sex differences

A review of the funnel plots could not rule out the potential for publication bias for CHD, stroke, cardiac death and all-cause mortality (online supplementary file 6). The Egger and Begg test results revealed no evidence of publication bias for CHD (Egger p=0.959; Begg p=0.245), stroke (Egger p=0.407; Begg p=0.398), cardiac death (Egger p=0.418; Begg p=0.721) and all-cause mortality (Egger p=0.118; Begg p=0.230).

DISCUSSION

The current investigation was based on a collection of prospective cohort studies and explored all possible sex differences between DM and the outcomes of CHD, stroke, cardiac death and all-cause mortality. This large quantitative study included 1 148 188 individuals and 52715DM patients from 30 prospective cohort studies investigating a broad range of populations. Findings from the current meta-analysis suggest that there are significant sex differences in DM versus non-DM regarding the incidence of CHD, stroke, cardiac death, all-cause mortality, with women demonstrating excessively higher risks than men. Furthermore, the findings of subgroup analyses could have been biased by publication year, country, sample size, assessment of DM, follow-up duration, adjustment for important cardiovascular risk factors and study quality.

Previous studies have suggested that women with DM have an increased risk for CHD or stroke compared with men with DM.¹³¹⁴ One of these investigations reported that the incidence of CHD was 44% greater in women with DM than in men with DM.¹³ Moreover, women with DM exhibited an increased risk for stroke compared with men with DM.¹⁴ However, sex differences regarding other important outcomes (cardiac death and all-cause mortality) were not evident. Therefore, we conducted this comprehensive quantitative meta-analysis of available prospective cohort studies to evaluate sex differences in DM and possible associations with major cardiovascular outcomes. Similar to previous meta-analyses, a significantly increased risk for cardiac death and all-cause mortality was observed in women with DM compared with men with DM. The excess risk for cardiac death in women with DM could be due to the higher risk for CHD

6			Open ac	cess
study	% rrr (95% Cl) Weight	study	rrr (95% Cl)	% Weight
Charleston Heart Study–Black	0.81 (0.09, 7)16 0.43	Collins–Indians	0.13 (0.01, 1.61)	0.23
Framingham study	0.89 (0.32, 2.41) 1.81	Takayama	0.53 (0.19, 1.50)	1.35
Advantist Health Study	1.02 (0.46, 2)26 2.69	DECODE	0.79 (0.41, 1.51)	3.40
Dubbo study	1.09 (0.60, 1.97) 4.27	Hisayama	0.80 (0.33, 1.90)	1.88
NHANESI	1.09 (0.57, 2.09) 3.73	APCSC-ANZ	0.87 (0.53, 1.44)	5.66
DECODE	1.19 (0.73, 1.93) 5.52	ESPro	0.88 (0.61, 1.26)	10.69
Charleston Heart Study–White	1.19 (0.26, 5.49) 0.84	NHANES III	1.13 (0.41, 3.16)	1.37
SHHEC	1.23 (0.78, 1.93) 6.06	Bancho Bernado	1.22 (0.47, 3.16)	1.59
APCSC-Asia	1.24 (0.66, 2.32) 3.89	lso	1.22 (0.53, 2.82)	2.05
APCSC-ANZ	1.27 (0.93, 1.75) 8.72	JACC	1.22 (0.95, 2.02)	17.70
Strong Heart Study 🔶	1.36 (0.95, 1)96 7.69	SHHEC	1.30 (0.68, 2.50)	3.36
HUNT 1 🔶	1.39 (1.14, 1.69) 11.71	JPHC	1.34 (0.84, 2.14)	6.51
JACC 🔶	1.40 (0.97, 2.00) 7.77	APCSC-Asia	1.35 (0.98, 1.87)	13.59
San Antonio Heart Study	1.46 (0.32, 6.71) 0.84	SALLS	1.33 (0.96, 1.87)	4.43
Reykjavik study	1.66 (0.99, 2.79) 5.14	Framingham Offspring		4.43
Renfrew and Paisley Survey	1.68 (0.93, 3)06 4.19	-	1.40 (0.32, 6.04)	
EPESE +	1.83 (0.69, 4.88) 1.88	EPIC–Norfolk	1.46 (0.65, 3.31)	2.15
Hawaii–Los Angeles–Hiroshima study	2.14 (1.00, 4)56 2.92	Kuopio and North Karelia	1.47 (0.86, 2.51)	5.00
Kuopio and North Karelia	2.32 (1.67, 3.21) 8.49	Dubbo study	1.53 (0.66, 3.53)	2.05
Hisayama 🕂 🕇	2.75 (1.01, 7)46 1.83	Collins–Melanesians	1.54 (0.15, 15.57)	
SALLS : 🛶	– 2.78 (2.02, 3.82) 8.70	ARIC	1.58 (1.15, 2.18)	13.85
Collins-Melanesians	3.35 (0.45, 24).86 0.50	Renfrew and Paisley Survey	1.86 (0.74, 4.71)	1.66
Collins–Indians	6.57 (0.66, 65.00) 0.39	Sievers	2.88 (0.57, 14.46)	
Overall (I-squared = 36.1%, p = 0.044)	1.52 (1.32, 1.76); 100.00	Overall (I–squared = 0.0%, p = 0.568)	1.23 (1.09, 1.39)	100.0
NOTE: Weights are from random effects analysis	P<0.001	NOTE: Weights are from random effects analysis	P=0.001	
.3 .5 1 2		.3 .5 1	2	

Figure 1 Sex differences in the associations between diabetes mellitus (DM) and the risk for coronary heart disease (CHD) (A) and stroke (B).

in women with DM, which may be due to the fact that women with DM have a greater adverse cardiovascular risk and are less likely to achieve recommended levels compared with men with DM. Cardiac death, as a part of CHD and the sex difference in the relationship between DM and CHD, was addressed in a previous meta-analysis.¹³ The death events were mostly caused by CVD in most of the included cohorts and may explain the significant sex differences in the association between DM and

A.CHD

all-cause mortality. Finally, the respective control group in men and women with different cardiovascular risk, which could affect sex differences in the associations between DM and cardiac death and all-cause mortality.

B. stroke

Findings from the subgroup analysis suggested that sex differences in the relationship between DM and major cardiovascular outcomes and all-cause mortality may vary according to predefined factors. First, publication year affected sex differences in the risk for stroke, which may

Variable	Group	Number of cohorts	RRR and 95% CI	P value	l ² (%)	P value for heterogeneity	P value for meta- regression
Publication year	Before 2010	20	1.53 (1.28 to 1.82)	<0.001	39.6	0.036	0.260
	2010 or after	3	1.42 (1.20 to 1.68)	<0.001	0.0	0.421	
Country	Western	18	1.50 (1.27 to 1.77)	< 0.001	43.6	0.025	0.934
	Eastern	5	1.58 (1.17 to 2.13)	0.003	6.7	0.368	
Sample size	≥10000	9	1.62 (1.31 to 2.00)	<0.001	65.4	0.003	0.119
	<10000	14	1.34 (1.09 to 1.63)	0.004	0.0	0.780	
Assessment of DM	Self-reported	6	1.75 (1.29 to 2.37)	<0.001	74.6	0.001	0.073
	Measured	13	1.32 (1.09 to 1.61)	0.005	0.0	0.764	
	Both	4	1.39 (1.11 to 1.75)	0.005	0.0	0.730	
Follow-up duration	≥10	16	1.69 (1.41 to 2.04)	< 0.001	43.1	0.034	0.032
(years)	<10	6	1.22 (0.98 to 1.52)	0.078	0.0	0.948	
Adjusted other	Yes	19	1.45 (1.29 to 1.62)	<0.001	6.6	0.375	<0.001
CVD risk factors	No	4	2.56 (1.89 to 3.46)	< 0.001	0.0	0.423	
Study quality	High	13	1.46 (1.29 to 1.66)	< 0.001	10.6	0.339	0.052
	Low	10	1.64 (1.14 to 2.36)	0.007	47.8	0.045	


CVD, cardiovascular disease.

Table 3 Subgroup analyses for stroke

Variable	Group	Number of cohorts	RRR and 95% CI	P value	l ² (%)	P value for heterogeneity	P value for meta- regression
Publication year	Before 2010	18	1.29 (1.11 to 1.50)	0.001	0.0	0.640	0.269
	2010 or after	4	1.11 (0.89 to 1.40)	0.353	18.1	0.300	
Country	Western	15	1.23 (1.05 to 1.44)	0.011	0.0	0.587	0.998
	Eastern	7	1.20 (0.97 to 1.49)	0.091	14.7	0.318	
Sample size	≥10000	14	1.25 (1.10 to 1.42)	<0.001	0.0	0.531	0.341
	<10000	8	1.04 (0.72 to 1.50)	0.840	0.0	0.493	
Assessment of	Self-reported	6	1.28 (1.04 to 1.58)	0.022	0.0	0.668	0.423
DM	Measured	11	1.32 (1.08 to 1.61)	0.008	0.0	0.508	
	Both	5	1.09 (0.85 to 1.41)	0.484	21.3	0.279	
Follow-up	≥10	18	1.28 (1.11 to 1.47)	0.001	0.0	0.726	0.313
duration (years)	<10	4	1.09 (0.76 to 1.57)	0.627	36.0	0.196	
Adjusted other	Yes	19	1.27 (1.11 to 1.44)	<0.001	0.0	0.695	0.237
CVD risk factors	No	3	1.14 (0.71 to 1.83)	0.586	40.4	0.187	
Study quality	High	16	1.24 (1.09 to 1.41)	0.001	0.0	0.533	0.617
	Low	6	1.13 (0.79 to 1.61)	0.498	2.4	0.401	

CVD, cardiovascular disease; RRR, relative risk ratio.

be due to advances in diagnostic approaches. Second, country (ie, hemisphere) could affect sex differences in DM and the risk for cardiac death and all-cause mortality, which could be explained by differences in the prevalence of cardiac death and all-cause mortality Eastern and Western countries. Third, sample size affected sex differences in the risk for stroke, cardiac death and all-cause mortality due to sample sizes being correlated with statistical power, which may have affected the ability to detect small differences. Fourth, the methods of assessing DM could affect sex differences in stroke, cardiac death and all-cause mortality because they may affect the prevalence of event rates. Fifth, follow-up duration could affect sex differences in the risk for CHD, stroke and cardiac death, because there were studies with longer follow-up and higher proportion of patients with CHD than studies with shorter follow-up, which contributed to the higher weight in pooled results and made it easier to detect small



A. cardiac death

B. all-cause mortality

Figure 2 Sex differences in the associations between diabetes mellitus (DM) and the risk for cardiac death (A) and all-cause mortality (B).

Table 4 Subgroup	oup analyses for	cardiac death					
Variable	Group	Number of cohorts	RRR and 95% CI	P value	l ² (%)	P value for heterogeneity	P value for meta- regression
Publication year	Before 2010	10	1.49 (1.11 to 2.00)	0.009	31.9	0.153	-
	2010 or after	0	-	-	-	-	
Country	Western	7	1.84 (1.45 to 2.32)	<0.001	3.6	0.399	0.010
	Eastern	3	0.97 (0.62 to 1.51)	0.891	0.0	0.870	
Sample size	≥10000	2	1.96 (1.54 to 2.49)	<0.001	0.0	0.591	0.015
	<10000	8	1.18 (0.85 to 1.64)	0.322	0.0	0.433	
Assessment of	Self-reported	2	2.05 (1.59 to 2.64)	<0.001	0.0	0.568	0.016
DM	Measured	7	1.10 (0.78 to 1.54)	0.588	0.0	0.586	
	Both	1	1.68 (0.93 to 3.06)	0.087	-	_	
Follow-up	≥10	8	1.57 (1.18 to 2.09)	0.002	21.8	0.256	0.257
duration (years)	<10	2	1.41 (0.42 to 4.68)	0.576	66.5	0.084	
Adjusted other	Yes	8	1.42 (1.02 to 1.98)	0.040	44.0	0.085	0.575
CVD risk factors	No	2	2.18 (0.79 to 6.03)	0.132	0.0	0.524	
Study quality	High	4	1.97 (1.56 to 2.48)	<0.001	0.0	0.864	0.006
	Low	6	1.10 (0.78 to 1.55)	0.593	0.0	0.417	

CVD, cardiovascular disease; DM, diabetes mellitus.

differences. Finally, the other major cardiovascular risk factors, regardless of whether they were adjusted for, and study quality affected sex differences in stroke, cardiac death and all-cause mortality. Pooled studies with high quality or those that adjusted for other cardiovascular risk factors could have obtained more reliable results.

Several strengths of this meta-analysis should be highlighted. First, given the comprehensive inclusion of

	ibgroup analyse				-			P value
Outcomes	Variable	Group	Number of cohorts	RRR and 95% CI	P value	l² (%)	P value for heterogeneity	for meta- regression
All-cause	Publication	Before 2010	7	1.51 (1.23 to 1.85)	<0.001	38.2	0.138	-
mortality	year	2010 or after	0	-	-	-	-	
	Country	Western	6	1.63 (1.41 to 1.88)	<0.001	8.2	0.364	0.039
		Eastern	1	0.71 (0.33 to 1.55)	0.394	-	-	
	Sample size	≥10000	3	1.66 (1.46 to 1.90)	<0.001	0.0	0.772	0.050
		<10000	4	1.06 (0.59 to 1.90)	0.844	43.7	0.149	
	Assessment	Self-reported	2	1.69 (1.46 to 1.95)	<0.001	0.0	0.669	0.123
of DM	Measured	4	1.06 (0.59 to 1.90)	0.844	43.7	0.149		
	Both	1	1.50 (1.03 to 2.19)	0.035	-	-		
	Follow-up	≥10	7	1.51 (1.23 to 1.85)	<0.001	38.2	0.138	-
	duration (years)	<10	0	-	-	-	-	
	Adjusted	Yes	4	1.50 (1.12 to 2.01)	0.006	39.4	0.176	0.850
	other CVD risk factors	No	3	1.33 (0.75 to 2.36)	0.321	57.6	0.095	
	Study quality	High	2	1.69 (1.41 to 2.02)	<0.001	0.0	0.490	0.414
		Low	5	1.25 (0.80 to 1.94)	0.329	53.3	0.073	

CVD, cardiovascular disease; DM, diabetes mellitus.

published studies with large sample sizes, the findings of the present study were more robust than any of those individual studies. Second, all studies included were prospectively designed and population based, which could mitigate—if not eliminate—uncontrolled biases. Third, large-scale studies including patients with a broad range of characteristics support the generalisability of the results given the global distribution of the included populations. Fourth, stratified results of sex differences in DM and major cardiovascular outcomes based on study or patient characteristics were calculated. Finally, heterogeneity among the included studies was resolved using multiple methods, and no publication bias was found, which supports the robustness of the pooled results.

However, several limitations of this meta-analysis should also be acknowledged. First, various adjustments for cardiovascular risk factors across the included studies may have affected the development of major cardiovascular outcomes, as would various DM types, DM assessment methods and the duration of DM. Publication bias is inevitable when searching databases given the variation in publication languages, and the number of published studies with negative results. Finally, data regarding background drug use were available in few studies, which may have affected the absolute risk for major cardiovascular outcomes.

In conclusion, the results of this study indicated that women with DM exhibited a greater risk for CHD, stroke, cardiac death and all-cause mortality compared with men with DM. Furthermore, the true sex differences for the association between DM and major cardiovascular outcomes was variable and based on several characteristics of the study or the patients involved. Sex differences in specific patient characteristics should be verified and clarified, along with other biological, behavioural or social factors in future larger-scale prospective studies.

Contributors HW contributed to conception and design; all authors contributed to acquisition, analysis and interpretation of data; HW and QX were involved in drafting or critical revision of the manuscript. All the authors approved the final version.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data available.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

 Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. *Circulation* 2001;104:2746–53.

- Chambless L, Keil U, Dobson A, et al. Population versus clinical view of case fatality from acute coronary heart disease: results from the WHO MONICA Project 1985-1990. Multinational MONItoring of Trends and Determinants in CArdiovascular Disease. *Circulation* 1997;96:3849–59.
- Odutayo A, Wong CX, Hsiao AJ, et al. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ 2016;354:i4482.
- 4. Mente A, O'Donnell M, Rangarajan S, *et al.* Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies. *Lancet* 2016;388:465–75.
- Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol 2015;3:514–25.
- Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a metaanalysis of individual patient data. *Lancet* 2014;384:591–8.
- Lu Y, Hajifathalian K, Ezzati M, et al. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants. *Lancet* 2014;383:970–83.
- Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. *Circulation* 1998;97:1837–47.
- Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care* 1993;16:434–44.
- Haffner SM, Lehto S, Rönnemaa T, *et al*. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med* 1998;339:229–34.
- 11. Bartnik M, Norhammar A, Rydén L. Hyperglycaemia and cardiovascular disease. *J Intern Med* 2007;262:145–56.
- Goff DC, Gerstein HC, Ginsberg HN, *et al.* Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Am J Cardiol* 2007;99:S4–S20.
- Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. *Diabetologia* 2014;57:1542–51.
- Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and metaanalysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. *Lancet* 2014;383:1973–80.
- Walden CE, Knopp RH, Wahl PW, et al. Sex differences in the effect of diabetes mellitus on lipoprotein triglyceride and cholesterol concentrations. N Engl J Med 1984;311:953–9.
- Stroup DF, Berlin JA, Morton SC, *et al.* Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA* 2000;283:2008–12.
- 17 Wells G, Shea B, O' Connell D. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa (ON): Ottawa Hospital Research Institute, 2009.
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88.
- Ades AE, Lu G, Higgins JP. The interpretation of randomeffects meta-analysis in decision models. *Med Decis Making* 2005;25:646–54.
- 20. Woodward M. *Epidemiology: study design and data analysis.* 2nd edn. Boca Raton, FL, USA: Chapman and Hall/CRC, 2005.
- 21 Deeks JJ, Higgins JPT, Altman DG. Analyzing data and undertaking meta-analyses. In: Higgins J, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions 5.0.1*. Oxford, UK: The Cochrane Collaboration, 2008.
- 22. Higgins JP, Thompson SG, Deeks JJ, *et al.* Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557–60.
- 23. Tobias A. Assessing the influence of a single study in meta-analysis. *Stata Tech Bull* 1999;47:15–17.
- 24. Egger M, Davey Smith G, Schneider M, *et al.* Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629–34.
- Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994;50:1088–101.
- Kleinman JC, Donahue RP, Harris MI, et al. Mortality among diabetics in a national sample. Am J Epidemiol 1988;128:389–401.
- 27. Barrett-Connor E, Khaw KT. Diabetes mellitus: an independent risk factor for stroke? *Am J Epidemiol* 1988;128:116–23.

<u>6</u>

- the atherosclerosis risk in communities (ARIC) study: design and objectives. Am J Epidemiol 1989;129:687–702.
- Fraser GE, Strahan TM, Sabaté J, et al. Effects of traditional coronary risk factors on rates of incident coronary events in a low-risk population. The Adventist Health Study. *Circulation* 1992;86:406–13.
- Sievers ML, Nelson RG, Knowler WC, et al. Impact of NIDDM on mortality and causes of death in Pima Indians. *Diabetes Care* 1992;15:1541–9.
- Seeman T, Mendes de Leon C, Berkman L, *et al.* Risk factors for coronary heart disease among older men and women: a prospective study of community-dwelling elderly. *Am J Epidemiol* 1993;138:1037–49.
- Keil JE, Sutherland SE, Knapp RG, et al. Mortality rates and risk factors for coronary disease in black as compared with white men and women. N Engl J Med 1993;329:73–8.
- Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Series 1: programs and collection procedures. *Vital Health Stat 1* 1994;11994:1–407.
- Simons LA, Friedlander Y, McCallum J, et al. Risk factors for coronary heart disease in the prospective Dubbo Study of Australian elderly. *Atherosclerosis* 1995;117:107–18.
- Collins VR, Dowse GK, Ram P, et al. Non-insulin-dependent diabetes and 11-year mortality in Asian Indian and Melanesian Fijians. *Diabet Med* 1996;13:125–32.
- Nilsson PM, Johansson SE, Sundquist J. Low educational status is a risk factor for mortality among diabetic people. *Diabet Med* 1998;15:213–9.
- Imazu M, Sumii K, Yamamoto H, et al. Influence of type 2 diabetes mellitus on cardiovascular disease mortality: findings from the Hawaii-Los Angeles-Hiroshima study. *Diabetes Res Clin Pract* 2002;57:61–9.
- Jónsdóttir LS, Sigfússon N, Gudnason V, et al. Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study. J Cardiovasc Risk 2002;9:67–76.
- Woodward M, Barzi F, Martiniuk A, et al. Cohort profile: the Asia Pacific Cohort Studies Collaboration. Int J Epidemiol 2006;35:1412–6.
- Natarajan S, Liao Y, Cao G, et al. Sex differences in risk for coronary heart disease mortality associated with diabetes and established coronary heart disease. Arch Intern Med 2003;163:1735–40.
- Iso H, Imano H, Kitamura A, et al. Type 2 diabetes and risk of nonembolic ischaemic stroke in Japanese men and women. *Diabetologia* 2004;47:2137–44.
- Whiteley L, Padmanabhan S, Hole D, et al. Should diabetes be considered a coronary heart disease risk equivalent?: results from 25 years of follow-up in the Renfrew and Paisley survey. *Diabetes Care* 2005;28:1588–93.

- Hu G, Jousilahti P, Qiao Q, et al. Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction. *Diabetologia* 2005;48:856–61.
- Lee ET, Howard BV, Wang W, et al. Prediction of coronary heart disease in a population with high prevalence of diabetes and albuminuria: the Strong Heart Study. *Circulation* 2006;113:2897–905.
- Najarian RM, Sullivan LM, Kannel WB, et al. Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: the Framingham Offspring Study. Arch Intern Med 2006;166:106–11.
- 46. Hunt KJ, Williams K, Hazuda HP, *et al*. The metabolic syndrome and the impact of diabetes on coronary heart disease mortality in women and men: the San Antonio Heart Study. *Ann Epidemiol* 2007;17:870–7.
- Woodward M, Brindle P, Tunstall-Pedoe H; SIGN group on risk estimation. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). *Heart* 2007;93:172–6.
- Myint PK, Sinha S, Luben RN, *et al.* Risk factors for first-ever stroke in the EPIC-Norfolk prospective population-based study. *Eur J Cardiovasc Prev Rehabil* 2008;15:663–9.
- Oba S, Nagata C, Nakamura K, et al. Self-reported diabetes mellitus and risk of mortality from all causes, cardiovascular disease, and cancer in Takayama: a population-based prospective cohort study in Japan. J Epidemiol 2008;18:197–203.
- Hyvärinen M, Tuomilehto J, Laatikainen T, et al. The impact of diabetes on coronary heart disease differs from that on ischaemic stroke with regard to the gender. Cardiovasc Diabetol 2009;8:17.
- Doi Y, Ninomiya T, Hata J, *et al.* Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general Japanese population: the Hisayama study. *Stroke* 2010;41:203–9.
- Cui R, Iso H, Yamagishi K, et al. Diabetes mellitus and risk of stroke and its subtypes among Japanese: the Japan public health center study. Stroke 2011;42:2611–4.
- Madssen E, Vatten L, Nilsen TI, et al. Abnormal glucose regulation and gender-specific risk of fatal coronary artery disease in the HUNT 1 study. Scand Cardiovasc J 2012;46:219–25.
- Icks A, Claessen H, Kvitkina T, et al. Incidence and relative risk of stroke in the diabetic and the non-diabetic population between 1998 and 2014: A community-based stroke register. *PLoS One* 2017;12:e0188306.
- 55. Matsunaga M, Yatsuya H, Iso H, *et al.* Similarities and differences between coronary heart disease and stroke in the associations with cardiovascular risk factors: The Japan Collaborative Cohort Study. *Atherosclerosis* 2017;261:124–30.